Author： Shinkai H.
Publisher： Informa Healthcare
ISSN： 1354-3776
Source： Expert Opinion on Therapeutic Patents, Vol.11, Iss.5, 2001-05, pp. : 739-745
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
As well as hypercholesterolaemia, low levels of high-density lipoprotein cholesterol (HDL-C) are critical risk factors for atherosclerosis and coronary heart disease (CHD). Although fibrate, simvastatin and niacin can be used for the treatment of a low HDL-C level, their effects, however, are not wholly satisfactory. Thus, better drugs for the elevation of HDL-C are desired. Among the many methods that may be used to raise HDL-C levels, this review focuses on small molecule inhibitors of cholesteryl ester transfer protein (CETP) and summarises recent patent and journal data.
Related content
Cholesteryl Ester Transfer Protein (CETP) Inhibitors
Current Topics in Medicinal Chemistry, Vol. 9, Iss. 5, 2009-04 ,pp. :
Access to resources
Recommend
